  0 目錄 |
  1 應用說明 |
| 2 Libraries |
| 3 Libraries下載 |
 4 Artifacts Summary |
 4.1 Abemaciclib給付規定-BC Abemaciclib Rule1 |
| 4.2 CDK46給付規定-BC CDK46 Rule1 |
| 4.3 乳癌代碼集-BCCodeConcept |
| 4.4 Everolimus給付規定-BC Everolimus Rule1 |
| 4.5 Larotrectinib給付規定-BC Larotrectinib Rule1 |
| 4.6 Olaparib給付規定(三陰性乳癌)-BC Olaparib Rule1 |
| 4.7 Olaparib給付規定(高復發風險早期乳癌)-BC Olaparib Rule2 |
| 4.8 Pembrolizumab給付規定(早期三陰性乳癌)-BC Pembrolizumab Rule |
| 4.9 Pertuzumab給付規定(早期乳癌)-BC Pertuzumab Rule1 |
| 4.10 Pertuzumab給付規定(移轉性乳癌)-BC Pertuzumab Rule2 |
| 4.11 Pertuzumab與Trastuzumab皮下注射複方製劑給付規定(早期乳癌)-BC PertuzumabTrastuzumabSC Rule1 |
| 4.12 Pertuzumab與Trastuzumab皮下注射複方製劑給付規定(移轉性乳癌)-BC PertuzumabTrastuzumabSC Rule2 |
| 4.13 乳癌規則共通模組-BCReusable |
| 4.14 Sacituzumab govitecan給付規定-BC Sacituzumab Govitecan Rule |
| 4.15 Talazoparib給付規定-BC Talazoparib Rule1 |
| 4.16 Trastuzumab Deruxtecan(早期乳癌_二線治療)給付規定-BC Trastuzumab Deruxtecan Rule1 |
| 4.17 Trastuzumab Deruxtecan(轉移性乳癌)給付規定-BC Trastuzumab Deruxtecan Rule2 |
| 4.18 Trastuzumab Emtansine(早期乳癌)給付規定-BC Trastuzumab Emtansine Rule1 |
| 4.19 Trastuzumab Emtansine(晚期乳癌)給付規定-BC Trastuzumab Emtansine Rule2 |
| 4.20 Trastuzumab給付規定-BC Trastuzumab Rule1 |
| 4.21 Trastuzumab(早期乳癌)給付規定-BC Trastuzumab Rule2 |
| 4.22 Trastuzumab(轉移性乳癌)給付規定-BC Trastuzumab Rule3 |
| 4.23 Bevacizumab給付規定(轉移性大腸或直腸癌患者的第一線治療)-CRC Bevacizumab Rule1 |
| 4.24 Bevacizumab給付規定(RAS基因沒有突變的轉移性大腸或直腸癌病人的第二線治療)-CRC Bevacizumab Rule2 |
| 4.25 Cetuximab給付規定(第一線治療)-CRC Cetuximab Rule1 |
| 4.26 Cetuximab給付規定(第二線(含)以上治療)-CRC Cetuximab Rule2 |
| 4.27 大腸直腸癌代碼集-CRCCodeConcept |
| 4.28 Larotrectinib給付規定-CRC Larotrectinib Rule1 |
| 4.29 Panitumumab給付規定-CRC Panitumumab Rule1 |
| 4.30 Pembrolizumab給付規定-CRC Pembrolizumab Rule1 |
| 4.31 Regorafenib給付規定-CRC Regorafenib Rule1 |
| 4.32 大腸直腸癌規則共通模組-CRCReusable |
| 4.33 Trifluridine/tipiracil給付規定-CRC Trifluridine/Tipiracil Rule1 |
| 4.34 Atezolizumab/Durvalumab給付規定(晚期肝細胞癌第一線用藥(併用))-HCC Atezolizumab/Durvalumab Rule1 |
| 4.35 肝癌代碼集-HCCCodeConcept |
| 4.36 Larotrectinib給付規定-HCC Larotrectinib Rule1 |
| 4.37 Lenvatinib給付規定-HCC Lenvatinib Rule1 |
| 4.38 Pemigatinib給付規定-HCC Pemigatinib Rule1 |
| 4.39 Ramucirumab給付規定-HCC Ramucirumab Rule1 |
| 4.40 Regorafenib給付規定-HCC Regorafenib Rule1 |
| 4.41 肝癌規則共通模組-HCCReusable |
| 4.42 Sorafenib給付規定-HCC Sorafenib Rule1 |
| 4.43 Alectinib給付規定-LC Alectinib Rule1 |
| 4.44 Atezolizumab、Durvalumab給付規定(小細胞肺癌)-LC Atezolizumab、Durvalumab Rule1 |
| 4.45 Bevacizumab給付規定-LC Bevacizumab Rule1 |
| 4.46 Brigatinib給付規定-LC Brigatinib Rule1 |
| 4.47 Ceritinib給付規定-LC Ceritinib Rule1 |
| 4.48 肺癌代碼集-LCCodeConcept |
| 4.49 Crizotinib給付規定-LC Crizotinib Rule1 |
| 4.50 Dabrafenib、Trametinib給付規定(非小細胞肺癌)-LC Dabrafenib、Trametinib Rule1 |
| 4.51 Durvalumab給付規定(非小細胞肺鞏固(單用))-LC Durvalumab Rule1 |
| 4.52 Entrectinib給付規定-LC Entrectinib Rule1 |
| 4.53 Larotrectinib給付規定-LC Larotrectinib Rule1 |
| 4.54 Lorlatinib給付規定-LC Lorlatinib Rule1 |
| 4.55 Osimertinib給付規定(肺腺癌之第一線治療)-LC Osimertinib Rule1 |
| 4.56 Osimertinib給付規定(非小細胞肺癌第二線治療)-LC Osimertinib Rule2 |
| 4.57 Pembrolizumab、Nivolumab、Atezolizumab給付規定(鱗狀非小細胞肺癌第二線用藥(單用))-LC Pembrolizumab、Nivolumab、Atezolizumab Rule1 |
| 4.58 Pembrolizumab、Nivolumab、Atezolizumab給付規定(非鱗狀非小細胞肺癌第三線用藥(單用))-LC Pembrolizumab、Nivolumab、Atezolizumab Rule2 |
| 4.59 Pembrolizumab、Atezolizumab給付規定(鱗狀、非鱗狀非小細胞肺癌第一線用藥(單用))-LC Pembrolizumab、Atezolizumab Rule1 |
| 4.60 Pembrolizumab、Atezolizumab給付規定(非鱗狀非小細胞肺癌第一線用藥(併用))-LC Pembrolizumab、Atezolizumab Rule2 |
| 4.61 Pembrolizumab給付規定(鱗狀非小細胞肺癌第一線用藥(併用))-LC Pembrolizumab Rule1 |
| 4.62 肺癌規則共通模組-LCReusable |
| 4.63 Tepotinib給付規定-LC Tepotinib Rule1 |
| 4.64 Abiraterone給付規定-PC Abiraterone Rule1 |
| 4.65 Apalutamide給付規定-PC Apalutamide Rule1 |
| 4.66 攝護腺癌代碼集-PCCodeConcept |
| 4.67 Darolutamide給付規定(與docetaxel併用於治療高風險轉移性的去勢敏感性前列腺癌(mCSPC))-PC Darolutamide Rule1 |
| 4.68 Darolutamide給付規定(治療高風險非轉移性去勢抗性前列腺癌(high risk nmCRPC)的成年男性)-PC Darolutamide Rule2 |
| 4.69 Enzalutamide給付規定(高風險非轉移性去勢抗性前列腺癌(high risk nmCRPC))-PC Enzalutamide Rule1 |
| 4.70 Enzalutamide給付規定(高風險轉移性的去勢敏感性前列腺癌(mCSPC))-PC Enzalutamide Rule2 |
| 4.71 Enzalutamide給付規定(藥物或手術去勢抗性的轉移性前列腺癌(mCRPC)-未化療)-PC Enzalutamide Rule3 |
| 4.72 Enzalutamide給付規定(藥物或手術去勢抗性的轉移性前列腺癌(mCRPC)-已化療)-PC Enzalutamide Rule4 |
| 4.73 Larotrectinib給付規定-PC Larotrectinib Rule1 |
| 4.74 Olaparib給付規定-PC Olaparib Rule1 |
| 4.75 Radium-223給付規定-PC Radium223 Rule1 |
| 4.76 攝護腺癌規則共通模組-PCReusable |
 4.77 FHIRHelpers |
